ResMed shares are tanking after trials indicate a sleep apnea treatment could be bad for you

Sleeping Beauty played by actress Elisabeth Knoche. Sean Gallup/Getty Images

ResMed shares are falling after scientific trials suggest that patients may be worse off using one of its sleep apnea treatments.

The trials found a “statistically significant” increased risk of cardiovascular mortality when using the Adaptive Servo-Ventilation (ASV) therapy. The cardiovascular mortality rate in the ASV group was 10% per year compared to 7.5% in the control group.

Glenn Richards, ResMed chief medical officer, said: “We are further analysing the data to understand why this unexpected result was observed in this trial.”

ResMed shares have been under pressure since it announced weaker results, posting a 1% rise in net revenue to $91 million for the March quarter. The result was on 6% rise in revenue to $422.5 million.

The company has been building devices and treatments for sleep-disordered breathing, chronic obstructive pulmonary disease and other chronic diseases for more than 25 years.

Its shares have been trading down 18% to $6.765.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.